Results indicated that the inclusion of L-FABP was 2.9 times more likely to correctly identify patients’ risk for AKI and were more than twice as likely to treat for AKI by providing volume expansion and withholding nephrotoxic medications. Here, FABP1 is linked to acute kidney injury.